Domača stranME • NASDAQ
add
23andMe Holding Co.
0,39 $
Po zaprtju:(5,55 %)+0,022
0,41 $
Konec trgovanja: 28. jun., 20:00:00 GMT -4 · USD · NASDAQ · Izjava
Prejšnji trg. dan.
0,42 $
Dnevni razpon
0,39 $ - 0,44 $
Letni razpon
0,35 $ - 2,03 $
Tržna kapitalizacija
183,57 mio. USD
Povprečni obseg
4,49 mio.
Razm. P/E
-
Dividendna donosnost
-
Primarna borza
NASDAQ
V novicah
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
(USD) | mar. 2024info | Sprememba L/L |
---|---|---|
Prihodek | 64,03 mio. | −30,69 % |
Stroški poslovanja | 53,15 mio. | −51,42 % |
Čisti dohodek | −208,83 mio. | −225,80 % |
Čista dobičkovnost prihodkov | −326,16 | −370,04 % |
Earnings per share | −0,43 | −206,96 % |
EBITDA | −22,06 mio. | 64,57 % |
Efektivna davčna stopnja | −0,01 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
(USD) | mar. 2024info | Sprememba L/L |
---|---|---|
Denar. in kratkor. naložbe | 216,49 mio. | −44,04 % |
Skupna sredstva | 395,17 mio. | −58,08 % |
Skupne obveznosti | 206,65 mio. | −9,63 % |
Celoten lastniški kapital | 188,52 mio. | — |
Shares outstanding | 490,26 mio. | — |
Razmerje P/B | 1,11 | — |
Donosnost sredstev | −13,02 % | — |
Donosnost kapitala | −18,11 % | — |
Denarni tok
Neto sprememba denarnih sredstev
(USD) | mar. 2024info | Sprememba L/L |
---|---|---|
Čisti dohodek | −208,83 mio. | −225,80 % |
Denar iz dejavnosti | −25,78 mio. | 42,65 % |
Denar iz naložb | −2,15 mio. | 34,73 % |
Denar iz financiranja | 2,00 mio. | −23,25 % |
Neto sprememba denarnih sredstev | −25,93 mio. | 43,57 % |
Prost denarni tok | 50,88 mio. | 282,19 % |
Vizitka
23andMe Holding Co. is an American personal genomics and biotechnology company based in South San Francisco, California. It is best known for providing a direct-to-consumer genetic testing service in which customers provide a saliva sample that is laboratory analysed, using single nucleotide polymorphism genotyping, to generate reports relating to the customer's ancestry and genetic predispositions to health-related topics. The company's name is derived from the 23 pairs of chromosomes in a diploid human cell.
Founded in 2006, 23andMe soon became the first company to begin offering autosomal DNA testing for ancestry, which all other major companies now use. Its saliva-based direct-to-consumer genetic testing business was named "Invention of the Year" by Time in 2008.
The company had a previously fraught relationship with the United States Food and Drug Administration due to its genetic health tests; as of October 2015, DNA tests ordered in the US include a revised health component, per FDA approval. 23andMe has been selling a product with both ancestry and health-related components in Canada since October 2014, and in the UK since December 2014. Wikipedia
Generalni direktor
Datum ustanovitve
apr. 2006
Sedež organizacije
Spletno mesto
Zaposleni
571